Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 12Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Urogenital Neoplasms 1Urogenital Diseases 1Thrombocytosis 1Refractory or Relapsed Solid Tumors 1Prostatic Diseases 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Male Urogenital Diseases 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

darolutamide 1Rifampin 1Itraconazole 1Hydroxychloroquine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Refractory or Relapsed Solid Tumors × darolutamide × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡